Plant Name: Rubia cordifolia
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPBAR1; ADRA2C; ADRA2A; | |
| NMUR2; | |
| PTPN1; PTPN2; CDC25B; | |
| PLA2G1B; RECQL; TDP1; PIK3CA; PIK3CB; PKM; GFER; HPGD; ALOX12; IDO1; NQO2; HSD17B10; ALOX15; AKR1B10; ALDH1A1; USP2; POLB; | |
| GAA; ACHE; | |
| BCL2; | |
| TRPV1; | |
| FYN; EGFR; MAPK1; | |
| CA1; CA12; CA9; CA13; CA2; CA5B; CA3; CA14; CA5A; CA4; CA6; CA7; | |
| ESR1; | |
| NR1H4; | |
| MAOB; MAOA; PTGS2; PTGS1; ALDH2; | |
| ELANE; | |
| CASP1; CASP7; | |
| TP53; NFKB1; HIF1A; | |
| SLC6A2; | |
| HTT; LMNA; NPC1; RAB9A; MAPT; THPO; MCL1; APP; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | IDO1 | Indoleamine 2,3-dioxygenase | P14902 | CHEMBL4685 |
| Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
| Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Oxidoreductase | MAOB | Monoamine oxidase B | P27338 | CHEMBL2039 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | ALDH2 | Aldehyde dehydrogenase | P05091 | CHEMBL1935 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Protein Kinase | FYN | Tyrosine-protein kinase FYN | P06241 | CHEMBL1841 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Serine protease | ELANE | Leukocyte elastase | P08246 | CHEMBL248 |
| SLC superfamily of solute carriers | SLC6A2 | Norepinephrine transporter | P23975 | CHEMBL222 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transient receptor potential channel | TRPV1 | Vanilloid receptor | Q8NER1 | CHEMBL4794 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | MCL1 | Induced myeloid leukemia cell differentiation protein Mcl-1 | Q07820 | CHEMBL4361 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 9.800E-11 | 8.891E-08 | ADRA2A, BCL2, CA2, CA7, EGFR, FYN, HIF1A, HTT, MAPK1, NPC1, NR1H4, PIK3CB, PLA2G1B, PTGS2, TRPV1 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 4.433E-10 | 3.114E-07 | CA2, CA7, EGFR, HIF1A, HTT, MAPK1, NPC1, NR1H4, PIK3CB, PLA2G1B, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.224E-09 | 9.884E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.980E-08 | 6.250E-06 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, NQO2, NR1H4, PTPN1, TP53 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 7.222E-08 | 1.865E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.741E-07 | 3.906E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 2.296E-07 | 4.772E-05 | AKR1B10, APP, CYP1A2, CYP2C19, CYP2C9, CYP3A4, ESR1, NPC1, NR1H4 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 2.627E-07 | 5.297E-05 | ALOX12, ALOX15, HPGD, PTGS2 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.649E-07 | 6.791E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4, IDO1, PTGS1, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 6.018E-07 | 1.032E-04 | CASP1, CYP1A2, ELANE, HPGD, IDO1, MAOB, NFKB1, NR1H4, PTGS2 |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 2.663E-06 | 3.624E-04 | ADRA2A, ADRA2C, FYN, MAPK1, PIK3CA, PIK3CB |
| MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 2.861E-06 | 3.870E-04 | BCL2, MAPT, PTPN1, TP53 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 3.278E-06 | 4.300E-04 | CYP1A2, CYP2C19, CYP2C9, CYP3A4, NQO2, PTGS1 |
| BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 3.609E-06 | 4.566E-04 | APP, EGFR, MAPT |
| BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 3.619E-06 | 4.566E-04 | ADRA2A, ALOX12, APP, BCL2, EGFR, ELANE, HIF1A, MAPK1, PTGS2, TP53 |
| BP | GO:0050896; response to stimulus | GO:0045471; response to ethanol | 3.627E-06 | 4.566E-04 | CA3, FYN, HPGD, MAOB, POLB, TP53 |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 4.538E-06 | 5.552E-04 | AKR1B10, ALDH1A1, ALOX12, ALOX15, APP, BCL2, CA1, CA13, CA2, CA3, CA7, CASP1, CASP7, CDC25B, FYN, GFER, HIF1A, HPGD, HTT, IDO1, LMNA, MAPK1, MAPT, MCL1, NFKB1, NQO2, PIK3CA, PIK3CB, PKM, PLA2G1B, PTPN1, PTPN2, RAB9A, TP53, TRPV1 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 5.142E-06 | 6.052E-04 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0065007; biological regulation | GO:0006874; cellular calcium ion homeostasis | 8.203E-06 | 9.208E-04 | APP, BCL2, ELANE, ESR1, HTT, NMUR2, PIK3CB, PLA2G1B, TRPV1 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 7.088E-28 | 1.543E-23 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 9.302E-06 | 1.018E-03 | BCL2, CA2, CA7, FYN, HTT, PLA2G1B, TRPV1 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 9.379E-06 | 1.020E-03 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0065007; biological regulation | GO:0010817; regulation of hormone levels | 1.246E-05 | 1.276E-03 | ACHE, ADRA2A, ADRA2C, ALDH1A1, CYP3A4, EGFR, ESR1, HIF1A, NFKB1, NR1H4 |
| BP | GO:0065007; biological regulation | GO:0043006; activation of phospholipase A2 activity by calcium-mediated signaling | 1.258E-05 | 1.276E-03 | EGFR, NMUR2 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.258E-05 | 1.276E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 1.258E-05 | 1.276E-03 | PTGS1, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.258E-05 | 1.276E-03 | ALOX12, ALOX15 |
| MF | GO:0005488; binding | GO:0042562; hormone binding | 1.320E-05 | 1.318E-03 | ACHE, ALDH1A1, EGFR, NQO2, PKM |
| BP | GO:0065007; biological regulation | GO:0032147; activation of protein kinase activity | 1.577E-05 | 1.533E-03 | ADRA2A, ADRA2C, EGFR, MAPK1, PIK3CA, PIK3CB, PLA2G1B, PTPN1 |
| CC | GO:0043226; organelle | GO:0070013; intracellular organelle lumen | 1.857E-05 | 1.758E-03 | ALDH2, APP, CA5A, CA5B, EGFR, ELANE, GAA, GFER, HSD17B10, MAPK1, MCL1, NFKB1, PKM, PTGS2, TP53 |
| BP | GO:0009987; cellular process | GO:0034605; cellular response to heat | 1.989E-05 | 1.851E-03 | MAPT, PTGS2, TP53, TRPV1 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.989E-05 | 1.851E-03 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 2.268E-05 | 2.075E-03 | BCL2, HIF1A, MCL1, PTGS2, PTPN1 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.291E-05 | 2.087E-03 | ALOX12, ALOX15, CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0009987; cellular process | GO:2000811; negative regulation of anoikis | 2.363E-05 | 2.135E-03 | BCL2, MCL1, PIK3CA |
| BP | GO:0032501; multicellular organismal process | GO:0048546; digestive tract morphogenesis | 2.363E-05 | 2.135E-03 | BCL2, EGFR, HIF1A |
| BP | GO:0008152; metabolic process | GO:0033138; positive regulation of peptidyl-serine phosphorylation | 2.769E-05 | 2.461E-03 | APP, BCL2, EGFR, PIK3CA, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0006979; response to oxidative stress | 2.968E-05 | 2.595E-03 | APP, BCL2, CA3, EGFR, MAPK1, PTGS1, PTGS2, TP53 |
| BP | GO:0050896; response to stimulus | GO:0032870; cellular response to hormone stimulus | 2.968E-05 | 2.595E-03 | ADRA2A, EGFR, ESR1, FYN, NFKB1, NPC1, PKM, PLA2G1B |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 3.511E-05 | 2.998E-03 | BCL2, HIF1A, LMNA, PTGS2, TP53 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.764E-05 | 3.105E-03 | CA2, CA7 |
| BP | GO:0019740; nitrogen utilization | GO:0006808; regulation of nitrogen utilization | 3.764E-05 | 3.105E-03 | BCL2, NR1H4 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 3.764E-05 | 3.105E-03 | GPBAR1, NR1H4 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 3.764E-05 | 3.105E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 3.764E-05 | 3.105E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 3.764E-05 | 3.105E-03 | ADRA2A, ADRA2C |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 3.764E-05 | 3.105E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 3.764E-05 | 3.105E-03 | GPBAR1, NR1H4 |
| BP | GO:0032501; multicellular organismal process | GO:0033555; multicellular organismal response to stress | 4.121E-05 | 3.311E-03 | BCL2, IDO1, NMUR2, SLC6A2 |
| BP | GO:0008152; metabolic process | GO:0009895; negative regulation of catabolic process | 4.207E-05 | 3.357E-03 | ADRA2A, BCL2, EGFR, FYN, MCL1, NPC1, PIK3CA |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 4.209E-05 | 3.357E-03 | ALDH2, CYP1A2, IDO1, MAOB, NQO2 |
| BP | GO:0065007; biological regulation | GO:0043406; positive regulation of MAP kinase activity | 4.310E-05 | 3.425E-03 | ADRA2A, EGFR, ELANE, MAPK1, PIK3CB, PLA2G1B, PTPN1 |
| BP | GO:0009987; cellular process | GO:2001244; positive regulation of intrinsic apoptotic signaling pathway | 4.761E-05 | 3.689E-03 | BCL2, MCL1, PTPN2, TP53 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 5.329E-05 | 4.072E-03 | ADRA2A, CA2, CA4, CA9, EGFR, HPGD |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.541E-05 | 4.189E-03 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0051179; localization | GO:0043269; regulation of ion transport | 5.739E-05 | 4.309E-03 | ADRA2A, APP, BCL2, CA2, CA7, FYN, HTT, MAOB, PLA2G1B, PTGS2 |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 7.511E-05 | 5.293E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 7.511E-05 | 5.293E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 7.511E-05 | 5.293E-03 | PTPN1, PTPN2 |
| BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 8.135E-05 | 5.660E-03 | CYP1A2, EGFR, ESR1, HPGD, PTGS2 |
| CC | GO:0016020; membrane | GO:0045121; membrane raft | 8.305E-05 | 5.741E-03 | APP, EGFR, FYN, MAPK1, NPC1, PTGS2, SLC6A2 |
| BP | GO:0032501; multicellular organismal process | GO:0006940; regulation of smooth muscle contraction | 8.566E-05 | 5.903E-03 | ADRA2A, ADRA2C, NMUR2, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0046934; phosphatidylinositol-4,5-bisphosphate 3-kinase activity | 9.094E-05 | 6.161E-03 | EGFR, FYN, PIK3CA, PIK3CB |
| BP | GO:0009987; cellular process | GO:0080135; regulation of cellular response to stress | 9.855E-05 | 6.504E-03 | APP, EGFR, HIF1A, MAPK1, MAPT, MCL1, PTGS2, PTPN1, PTPN2, TP53 |
| BP | GO:0050896; response to stimulus | GO:1901653; cellular response to peptide | 9.887E-05 | 6.504E-03 | APP, FYN, NFKB1, PKM, PLA2G1B, TP53 |
| BP | GO:0009987; cellular process | GO:0008630; intrinsic apoptotic signaling pathway in response to DNA damage | 1.022E-04 | 6.664E-03 | BCL2, MCL1, POLB, TP53 |
| MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 1.102E-04 | 7.040E-03 | ACHE, ADRA2A, ADRA2C, BCL2, HPGD, MAOB, MAPT, MCL1, NFKB1, NQO2, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0010507; negative regulation of autophagy | 1.210E-04 | 7.657E-03 | BCL2, MCL1, NPC1, PIK3CA |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 1.249E-04 | 7.770E-03 | ALOX12, ALOX15 |
| MF | GO:0005488; binding | GO:0051434; BH3 domain binding | 1.249E-04 | 7.770E-03 | BCL2, MCL1 |
| BP | GO:0007610; behavior | GO:0007612; learning | 1.258E-04 | 7.806E-03 | APP, FYN, HIF1A, HTT, PTGS2 |
| BP | GO:0032501; multicellular organismal process | GO:0051241; negative regulation of multicellular organismal process | 1.278E-04 | 7.908E-03 | ADRA2C, ALOX12, APP, BCL2, EGFR, ELANE, HIF1A, IDO1, LMNA, NFKB1, NR1H4, PTGS2, PTPN2 |
| BP | GO:0050896; response to stimulus | GO:0048545; response to steroid hormone | 1.311E-04 | 8.015E-03 | BCL2, CA2, EGFR, MAOB, NPC1, PTGS2 |
| BP | GO:0009987; cellular process | GO:0051289; protein homotetramerization | 1.421E-04 | 8.572E-03 | HSD17B10, PKM, TP53, TRPV1 |
| BP | GO:0009987; cellular process | GO:0010821; regulation of mitochondrion organization | 1.556E-04 | 9.183E-03 | BCL2, HIF1A, HTT, LMNA, MAPT, TP53 |
| BP | GO:0008283; cell proliferation | GO:0048661; positive regulation of smooth muscle cell proliferation | 1.576E-04 | 9.275E-03 | EGFR, ELANE, HPGD, PTGS2 |
| CC | GO:0044464; cell part | GO:0005739; mitochondrion | 1.600E-04 | 9.389E-03 | BCL2, CA5A, CA5B, CASP1, FYN, GFER, HSD17B10, MAOA, MAOB, MAPK1, MCL1, NFKB1, PKM, TP53 |
| BP | GO:0009987; cellular process | GO:1901216; positive regulation of neuron death | 1.658E-04 | 9.665E-03 | FYN, MAPT, MCL1, TP53 |
| BP | GO:0009987; cellular process | GO:0050852; T cell receptor signaling pathway | 1.699E-04 | 9.866E-03 | FYN, MAPK1, NFKB1, PIK3CA, PIK3CB |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.035E-20 | 3.305E-16 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.931E-19 | 2.128E-15 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 6.316E-27 | 1.143E-24 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 5.195E-12 | 4.701E-10 | CYP2C9; APP; MAOB; MAOA; ALOX15; MAPK1; ALOX12; CYP2C19; PTGS2; PTGS1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.236E-09 | 5.592E-08 | CASP7; PIK3CA; LMNA; BCL2; MAPK1; PIK3CB; TP53; NFKB1; MCL1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.801E-09 | 6.520E-08 | CYP2C9; PLA2G1B; ALOX15; ALOX12; CYP2C19; PTGS2; PTGS1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 6.024E-10 | 3.635E-08 | CYP2C9; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 3.142E-09 | 9.478E-08 | PKM; PIK3CA; MAPK1; PIK3CB; TP53; HIF1A; EGFR |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 2.345E-08 | 6.063E-07 | PIK3CA; BCL2; MAPK1; PIK3CB; TP53; EGFR; NFKB1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.338E-07 | 2.245E-06 | MAOB; PLA2G1B; MAOA; GAA; ALOX15; ALOX12; PTGS2; CYP2C19; CYP3A4; HSD17B10; PTGS1; CYP2C9; PKM; AKR1B10; ALDH2; CYP1A2; ALDH1A1; IDO1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.043E-07 | 2.097E-06 | PIK3CA; MAPK1; PIK3CB; TP53; EGFR; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 6.491E-08 | 1.469E-06 | PIK3CA; BCL2; MAPK1; PIK3CB; HIF1A; EGFR; NFKB1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.365E-07 | 2.245E-06 | CYP2C9; MAOB; MAOA; CYP1A2; CYP3A4; CYP2C19 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.861E-07 | 2.807E-06 | PIK3CA; BCL2; MAPK1; FYN; PIK3CB; TP53; NFKB1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 8.080E-07 | 9.750E-06 | PIK3CA; BCL2; MAPK1; PTGS2; TP53; EGFR; NFKB1; CDC25B; MCL1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 5.111E-07 | 6.608E-06 | PIK3CA; BCL2; PIK3CB; PTGS2; TP53; NFKB1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 2.527E-07 | 3.518E-06 | MAOB; ALDH2; MAOA; CYP1A2; IDO1 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 2.301E-06 | 2.121E-05 | ACHE; PIK3CA; BCL2; MAPK1; FYN; PIK3CB |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.406E-06 | 1.497E-05 | PIK3CA; MAPK1; PIK3CB; TP53; EGFR |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 2.182E-06 | 2.121E-05 | CASP7; PIK3CA; MAPK1; PIK3CB; PTGS2; NFKB1 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 9.667E-07 | 1.094E-05 | PIK3CA; MAPK1; PIK3CB; TP53; EGFR |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 2.968E-06 | 2.558E-05 | PIK3CA; MAPK1; PIK3CB; TP53; EGFR |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 3.286E-06 | 2.703E-05 | PIK3CA; MAPK1; PIK3CB; TP53; ESR1; HIF1A |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 3.623E-06 | 2.851E-05 | PIK3CA; BCL2; MAPK1; PIK3CB; TP53; NFKB1 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 2.344E-06 | 2.121E-05 | PIK3CA; BCL2; MAPK1; PIK3CB; TP53 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 6.339E-06 | 4.219E-05 | PIK3CA; MAPK1; PIK3CB; TP53; HIF1A; ESR1; EGFR |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 8.652E-06 | 5.052E-05 | PIK3CA; BCL2; MAPK1; PIK3CB; PTGS2; HIF1A; TP53; EGFR; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 6.759E-06 | 4.219E-05 | POLB; PKM; PIK3CA; MAPK1; PIK3CB; TP53; NFKB1 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 4.604E-06 | 3.472E-05 | PIK3CA; MAPK1; PIK3CB; TP53; EGFR |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 4.934E-06 | 3.572E-05 | PIK3CA; MAPK1; PIK3CB; ESR1; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 6.566E-06 | 4.219E-05 | PIK3CA; MAPK1; PIK3CB; TP53; EGFR; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 5.283E-06 | 3.678E-05 | PIK3CA; MAPK1; PIK3CB; TP53; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 7.465E-06 | 4.504E-05 | PIK3CA; RAB9A; FYN; PIK3CB; TP53; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.121E-05 | 6.148E-05 | PIK3CA; BCL2; MAPK1; PIK3CB; TP53; NFKB1 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 2.225E-05 | 1.132E-04 | PIK3CA; BCL2; MAPK1; PIK3CB; TP53; EGFR; NFKB1; MCL1 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 1.757E-05 | 9.354E-05 | PIK3CA; THPO; BCL2; PIK3CB; PTPN2; MCL1 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 2.586E-05 | 1.200E-04 | PIK3CA; BCL2; MAPK1; PIK3CB; NFKB1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.347E-05 | 1.148E-04 | PIK3CA; MAPK1; PIK3CB; ESR1; EGFR |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 2.586E-05 | 1.200E-04 | PIK3CA; MAPK1; PIK3CB; HIF1A; EGFR |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 9.369E-06 | 5.299E-05 | CYP2C9; CYP1A2; CYP3A4; CYP2C19; PTGS2 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 2.978E-05 | 1.348E-04 | PIK3CA; MAPK1; FYN; PIK3CB; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 5.459E-05 | 2.250E-04 | PIK3CA; BCL2; MAPK1; PIK3CB; NFKB1 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 6.960E-05 | 2.680E-04 | PIK3CA; BCL2; MAPK1; FYN; PIK3CB; EGFR |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 6.399E-05 | 2.518E-04 | PIK3CA; MAPK1; FYN; PIK3CB; PTGS1 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.321E-04 | 4.270E-04 | PIK3CA; PLA2G1B; MAPK1; PIK3CB; EGFR; NFKB1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 9.298E-05 | 3.236E-04 | PIK3CA; MAPK1; FYN; PIK3CB; NFKB1 |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 1.400E-04 | 4.447E-04 | PIK3CA; MAPK1; FYN; PIK3CB; EGFR |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 2.480E-04 | 7.482E-04 | MAPK1; MAPT; TP53; EGFR; NFKB1; CDC25B |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 2.159E-04 | 6.739E-04 | PIK3CA; MAPK1; PIK3CB; PTGS2; EGFR |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 4.162E-05 | 1.837E-04 | PIK3CA; PIK3CB; PTGS2; PTGS1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 4.464E-05 | 1.924E-04 | PIK3CA; MAPK1; PIK3CB; NFKB1 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 5.469E-05 | 2.250E-04 | PIK3CA; MAPK1; PIK3CB; HIF1A |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 2.251E-05 | 1.132E-04 | PKM; PIK3CA; MAPK1; PIK3CB |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 5.837E-05 | 2.348E-04 | PIK3CA; MAPK1; PIK3CB; PTGS2 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 2.791E-04 | 8.281E-04 | PIK3CA; MAPK1; PIK3CB; ADRA2C; ADRA2A |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 8.945E-05 | 3.175E-04 | PIK3CA; MAPK1; FYN; PIK3CB |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 2.869E-04 | 8.376E-04 | APP; CASP7; MAPK1; MAPT; HSD17B10 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 3.462E-04 | 9.641E-04 | PIK3CA; CASP1; MAPK1; PIK3CB; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.180E-04 | 4.030E-04 | PIK3CA; MAPK1; PIK3CB; NFKB1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 7.958E-05 | 2.881E-04 | PIK3CA; MAPK1; PIK3CB; HIF1A |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 2.328E-04 | 7.140E-04 | PIK3CA; MAPK1; PIK3CB; EGFR |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 6.656E-04 | 1.650E-03 | PIK3CA; BCL2; PIK3CB; TP53; NFKB1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 7.495E-05 | 2.789E-04 | CYP2C9; CYP1A2; ALDH1A1; CYP3A4 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 3.132E-04 | 8.997E-04 | PIK3CA; PIK3CB; TP53; NFKB1 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 3.671E-04 | 9.918E-04 | PIK3CA; MAPK1; PIK3CB; CDC25B |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.244E-04 | 4.171E-04 | PTPN1; MAPK1; FYN; EGFR |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 3.671E-04 | 9.918E-04 | PIK3CA; ALOX12; TRPV1; PIK3CB |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 4.945E-04 | 1.279E-03 | PIK3CA; MAPK1; PIK3CB; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 5.495E-04 | 1.401E-03 | PTPN1; PIK3CA; PIK3CB; NFKB1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 1.311E-04 | 4.270E-04 | CASP7; CASP1; MAPK1; NFKB1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 4.601E-04 | 1.207E-03 | PIK3CA; MAPK1; PIK3CB; NFKB1 |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 1.157E-03 | 2.684E-03 | PIK3CA; MAPK1; PIK3CB; EGFR |
| hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 1.222E-03 | 2.800E-03 | PIK3CA; MAPK1; FYN; PIK3CB |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.972E-03 | 4.199E-03 | POLB; PIK3CA; PIK3CB; TP53; NFKB1 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.845E-03 | 4.023E-03 | CASP7; PIK3CA; PIK3CB; NFKB1 |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 1.714E-03 | 3.784E-03 | PIK3CA; BCL2; MAPK1; PIK3CB |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.361E-03 | 3.080E-03 | PTPN1; PIK3CA; MAPK1; PIK3CB |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 3.479E-03 | 6.998E-03 | HPGD; TP53; ELANE; NFKB1 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 3.986E-03 | 7.842E-03 | PIK3CA; MAPK1; PIK3CB; NFKB1 |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 6.098E-03 | 1.115E-02 | PIK3CA; MAPK1; PIK3CB; EGFR |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 6.405E-03 | 1.151E-02 | PIK3CA; MAPK1; PIK3CB; EGFR |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 4.966E-03 | 9.243E-03 | PIK3CA; MAPK1; PIK3CB; NFKB1 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.540E-02 | 2.558E-02 | NMUR2; TRPV1; ADRA2C; ADRA2A |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 1.305E-02 | 2.187E-02 | PIK3CA; MAPK1; PIK3CB |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 2.366E-02 | 3.598E-02 | BCL2; MAPK1; NFKB1 |
| hsa05034 | Alcoholism_Homo sapiens_hsa05034 | 2.400E-02 | 3.620E-02 | MAOB; MAOA; MAPK1 |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 4.086E-03 | 7.867E-03 | PIK3CA; MAPK1; PIK3CB |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 5.004E-03 | 9.243E-03 | PIK3CA; PIK3CB; NFKB1 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 4.086E-03 | 7.867E-03 | BCL2; PTGS2; NFKB1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 3.278E-03 | 6.666E-03 | CASP1; MAPK1; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 2.057E-03 | 4.279E-03 | MAPK1; PTGS2; NFKB1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.057E-03 | 4.279E-03 | CYP2C9; CYP1A2; CYP3A4 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.899E-03 | 4.092E-03 | CA2; NR1H4; CYP3A4 |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 2.977E-02 | 4.416E-02 | PIK3CA; PIK3CB |
| hsa00562 | Inositol phosphate metabolism_Homo sapiens_hsa00562 | 2.502E-02 | 3.742E-02 | PIK3CA; PIK3CB |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 1.006E-03 | 2.366E-03 | CASP1; MAPK1; NFKB1 |
| hsa05031 | Amphetamine addiction_Homo sapiens_hsa05031 | 2.245E-02 | 3.474E-02 | MAOB; MAOA |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 2.061E-02 | 3.272E-02 | PIK3CA; PIK3CB |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 9.068E-04 | 2.160E-03 | CASP7; CASP1; NFKB1 |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 2.308E-02 | 3.541E-02 | EGFR; NFKB1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 2.122E-02 | 3.339E-02 | MAPK1; NFKB1 |
| hsa04623 | Cytosolic DNA-sensing pathway_Homo sapiens_hsa04623 | 2.061E-02 | 3.272E-02 | CASP1; NFKB1 |
| hsa00010 | Glycolysis / Gluconeogenesis_Homo sapiens_hsa00010 | 2.245E-02 | 3.474E-02 | PKM; ALDH2 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 6.463E-04 | 1.625E-03 | MAOB; MAOA; NFKB1 |
| hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 7.269E-04 | 1.754E-03 | BCL2; CASP1; TP53 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 1.768E-02 | 2.858E-02 | AKR1B10; ALDH2 |
| hsa00330 | Arginine and proline metabolism_Homo sapiens_hsa00330 | 6.858E-04 | 1.678E-03 | MAOB; ALDH2; MAOA |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.712E-02 | 2.794E-02 | CYP1A2; CYP3A4 |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 3.286E-04 | 9.293E-04 | PIK3CA; MAPK1; PIK3CB |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 3.814E-04 | 1.015E-03 | MAPK1; TP53; EGFR |
| hsa00280 | Valine, leucine and isoleucine degradation_Homo sapiens_hsa00280 | 1.195E-02 | 2.021E-02 | ALDH2; HSD17B10 |
| hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 1.055E-02 | 1.802E-02 | PIK3CA; PIK3CB |
| hsa05020 | Prion diseases_Homo sapiens_hsa05020 | 6.485E-03 | 1.151E-02 | MAPK1; FYN |
| hsa00260 | Glycine, serine and threonine metabolism_Homo sapiens_hsa00260 | 8.408E-03 | 1.449E-02 | MAOB; MAOA |
| hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 8.408E-03 | 1.449E-02 | PKM; ALDH2 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 4.484E-03 | 8.544E-03 | MAPK1; TP53 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 4.794E-03 | 9.039E-03 | AKR1B10; GAA |
| hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 3.894E-03 | 7.746E-03 | MAPK1; EGFR |
| hsa00340 | Histidine metabolism_Homo sapiens_hsa00340 | 7.552E-05 | 2.789E-04 | MAOB; ALDH2; MAOA |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 6.485E-03 | 1.151E-02 | MAOB; MAOA |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 6.851E-03 | 1.204E-02 | AKR1B10; ALDH2 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 2.832E-03 | 5.825E-03 | CA2; CA4 |
| hsa00360 | Phenylalanine metabolism_Homo sapiens_hsa00360 | 1.543E-03 | 3.448E-03 | MAOB; MAOA |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.713E-02 | 2.794E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2; ADRA2C; APP; MAOB; ACHE; ACHE; ACHE; MAPT; MAOA |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C; PLA2G1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; SLC6A2; MAOB; ACHE; MAOA |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | SLC6A2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Idiopathic parkinson's disease | F02.3, G20 | MAOB |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2; EGFR; EGFR |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| C00-D49: Neoplasms | Glioma | C71 | EGFR; EGFR; APP |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; ADRA2C; ACHE |
| NA: NA | Geographic retinal atrophy | NA | APP |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
| C00-D49: Neoplasms | Neuroendocrine cancer | C7A | SLC6A2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAOB; ACHE; MAPT |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; ADRA2C; APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| NA: NA | Acute respiratory distress syndrome | NA | ELANE; ELANE; ELANE |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| NA: NA | Esophagus sensitivity | NA | TRPV1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| K00-K95: Diseases of the digestive system | Gastroesophageal reflux disease | K21 | TRPV1 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR |
| C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | TRPV1 |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADRA2C; SLC6A2 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; EGFR; EGFR; EGFR |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | IDO1; ADRA2C; SLC6A2; SLC6A2; SLC6A2; SLC6A2; MAOB; MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | MAOB |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1 |
| J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | ELANE; ELANE; ELANE |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | TRPV1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | TRPV1; PTGS1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS2; ELANE; PLA2G1B; PTGS1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PTGS2; PTGS2; PTGS2; PTGS2; ESR1; PKM; ADRA2C; ADRA2A; SLC6A2; ACHE; TRPV1; TRPV1; PTGS1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2; EGFR |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; EGFR |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | TRPV1; TRPV1 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; EGFR |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | BCL2; CA9; EGFR; HIF1A |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4; ACHE |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAOB; ACHE; MAPT |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | SLC6A2; MAOB; MAOA; MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive episode without melancholia | F30-F39 | MAOB |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | ALDH2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; ADRA2C; SLC6A2; MAOB |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; PTGS2; PTGS2; PTGS2; ELANE; CASP1; PLA2G1B |
| C00-D49: Neoplasms | Melanoma | C43 | EGFR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | PIK3CB |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| A00-B99: Certain infectious and parasitic diseases | Postherpetic neuralgia | B02.2, G44.847, G53.0 | TRPV1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | SLC6A2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | BCL2; BCL2; PTGS2; PIK3CA; PIK3CB; CA1; TP53; CA9; IDO1; NFKB1; EGFR; ESR1; ESR1; MAPK1; APP; ACHE; MCL1; CDC25B; HIF1A; NQO2 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOB; MAOB; ACHE; MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C; ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| C00-D49: Neoplasms | Prostate cancer | C61 | BCL2; EGFR; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| I00-I99: Diseases of the circulatory system | Moderate to severe hypertension | I10-I16 | MAOB |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS1 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| NA: NA | Motor symptoms | NA | MAOB |
| J00-J99: Diseases of the respiratory system | Mucolytic | J00-J99 | ELANE |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | BCL2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | TRPV1 |
| A00-B99: Certain infectious and parasitic diseases | Septic shock | A41.9 | ELANE |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; ELANE; ADRA2C; PLA2G1B; TRPV1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; PTGS2; PLA2G1B |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; EGFR; EGFR; PTGS1 |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP; ACHE |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | TRPV1 |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | ELANE |
| NA: NA | Myocardial ischaemia-reperfusion injury | NA | ELANE |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; PTGS2; GPBAR1; NFKB1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | BCL2; EGFR |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ELANE; ELANE |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pathological pain | R52, G89 | TRPV1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | BCL2; EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Leukemia | C90-C95 | BCL2; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; PTGS2; TRPV1; MAOA; PTGS1 |
| C00-D49: Neoplasms | Neuroblastoma | C74.1, C74.9, C75.4, C75.5, D35.0, D35.5, D35.6, D44.6, D44.7 | SLC6A2 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| C00-D49: Neoplasms | Breast cancer | C50 | BCL2; CA9; EGFR; EGFR; EGFR; ESR1; ESR1; NQO2 |
| J00-J99: Diseases of the respiratory system | Pulmonary emphysema | J43 | ELANE |
| J00-J99: Diseases of the respiratory system | Pulmonary disease | J00-J99 | ELANE |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; MAOB |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | TRPV1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A; SLC6A2; SLC6A2 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; ALDH2 |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAOB; MAPT |
| C00-D49: Neoplasms | Colon cancer | C50 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | ELANE; ELANE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C; SLC6A2 |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1; MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PIK3CA; TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | PIK3CA; PIK3CB; TP53; CA9; EGFR; PKM; MAPK1; HIF1A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; PTGS1 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cancer pain | R52, G89 | SLC6A2 |
| J00-J99: Diseases of the respiratory system | Bronchiectasis | J47, Q33.4 | ELANE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS2; PTGS2; PTGS2; PTGS2; ESR1; PTGS1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2; PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2C; MAOA; ALDH2 |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; EGFR; ESR1 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Acute or chronic pain | R52, G89 | TRPV1 |
| NA: NA | Colour dead tissues | NA | PTPN1 |